<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956695</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2012-05</org_study_id>
    <secondary_id>2012-003786-17</secondary_id>
    <nct_id>NCT01956695</nct_id>
  </id_info>
  <brief_title>Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma</brief_title>
  <acronym>REVRI</acronym>
  <official_title>Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because Primary Central Nervous System Lymphoma (PCNSL) are mainly diffuse large B-cell&#xD;
      lymphoma of the activated B cells (ABC) type, the investigators hypothesize that the synergy&#xD;
      of lenalidomide with rituximab shown in systemic non-Hodgkin's lymphoma (NHL) could be&#xD;
      observed in PCNSL.&#xD;
&#xD;
      This study will assess the efficiency of the the combination of lenalidomide and rituximab in&#xD;
      relapsed/refractory PCNSL, and the efficiency of a maintenance treatment with lenalidomide&#xD;
      alone in maintaining the response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators use a two-stage Fleming's design based on the following hypotheses under&#xD;
      treatment: 10% (null hypothesis, minimal clinical benefit rate), 30% (alternative hypothesis,&#xD;
      acceptable clinical benefit rate), 3% type I error rate, 5% type II error rate. Under these&#xD;
      hypotheses, a total of 45 assessable patients will be necessary: 22 for the first stage + 23&#xD;
      for the second stage.&#xD;
&#xD;
      Stage 1: following the inclusion of the first 22 assessable patients, if 0 or 1 patient has&#xD;
      an objective response (CR, Complete Response + uCR, unconfirmed Complete Response + PR,&#xD;
      Partial Response) at the end of induction treatment, the study would be terminated early and&#xD;
      the treatment will be considered ineffective. If 2 or more patients have an objective&#xD;
      response at the end of induction treatment, then the treatment will be considered as&#xD;
      effective in this indication. Otherwise, the second group of 23 patients will be recruited.&#xD;
&#xD;
      Stage 2: if at the end of recruitment, 8 or less patients have an objective response, the&#xD;
      investigators will conclude to inefficacy, and if 9 or more patients have an objective&#xD;
      response, then the treatment will be considered as effective and need further exploration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2013</start_date>
  <completion_date type="Actual">January 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 11, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the efficacy of lenalidomide in combination with rituximab in relapsed/refractory PCNSL as measured by the objective response rate (CR + uCR + PR) at the end of the 8 cycles of induction therapy.</measure>
    <time_frame>33 months</time_frame>
    <description>The objective response rate (CR+uCR+PR) will be evaluated according to the IPCG (International Primary CNS lymphoma Collaborative Group) recommendations. Patients will have an cerebral MRI, an ophthalmological examination and a lumbar puncture at several times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety of the association during induction and maintenance therapy in a population of PCNSL (NCI V4)</measure>
    <time_frame>56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of response</measure>
    <time_frame>56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive Free Survival at one year from the date of inclusion to the date of progression of the disease or death</measure>
    <time_frame>56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival from the date of inclusion to the date of death</measure>
    <time_frame>56 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using QLQ-C30 EORTC (European Organization for Research and Treatment of Cancer) questionnaire</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploration of T cells and NK (Natural Killer) cells populations in PCNSL before and after treatment to correlate possible changes of these populations with therapeutic response</measure>
    <time_frame>33 months</time_frame>
    <description>Pilot exploration of T cells and NK cells populations in PCNSL before and after treatment with the combination of lenalidomide-rituximab and to correlate possible changes of these populations with therapeutic response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Lymphoma</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>Lenalidomide &amp; Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.&#xD;
Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Lenalidomide &amp; Rituximab</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>Lenalidomide &amp; Rituximab</arm_group_label>
    <other_name>Mabthera®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 18 years old with a refractory or relapse PCNSL and who have previously&#xD;
             received at least high dose methotrexate (&gt; 1.5 g/m²) and high dose cytarabine (2&#xD;
             g/m²).&#xD;
&#xD;
          2. Patients can have received radiotherapy or intensive chemotherapy with hematopoietic&#xD;
             stem cell rescue as part of treatment of the PCNSL or IOL&#xD;
&#xD;
          3. Patients over 18 years old with a refractory or relapse IOL and who have received&#xD;
             either intravenous high dose methotrexate (&gt; 1.5 g/m2) or intraocular methotrexate&#xD;
&#xD;
          4. Life expectancy &gt; 2 months&#xD;
&#xD;
          5. Able to swallow capsules (stomach tube not allowed)&#xD;
&#xD;
          6. Adequate bone marrow function with absolute leukocytes &gt; 2000/mm3, neutrophil count&#xD;
             (ANC) &gt; 1000/mm3, haemoglobin &gt; 8 g/dl and platelets &gt; 100 000/mm3&#xD;
&#xD;
          7. Adequate liver function with Serum SGOT/AST or SGPT/ALT &lt; 3.0 X Upper Limit of Normal&#xD;
             ULN ; bilirubin &lt; 1.5 X LNS (excepted in case of hemolytic anemia or Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          8. Calculated creatinine clearance &gt; 40 ml/min. Patients with calculated creatinine&#xD;
             clearance between 40 and 50ml/min lenalidomide dose will be adjusted as follows (10mg&#xD;
             once daily)&#xD;
&#xD;
          9. Patient aged 18 years old or more and without measure of legal protection&#xD;
&#xD;
         10. Able to understand teratogenic risks of the treatment&#xD;
&#xD;
         11. Females of childbearing potential (FCBP) must agree to use two reliable forms of&#xD;
             contraception simultaneously or to practice complete abstinence from heterosexual&#xD;
             contact during the following time periods related to this study for at least four&#xD;
             weeks before starting study drug, while participating in the studyand for at least 4&#xD;
             weeks after discontinuation of Lenalidomide and 1 year after Rituximab.. Pregnancy&#xD;
             tests (serum β-HCG dosage) will be negative at baseline and during the study. Men must&#xD;
             agree not to procreate a child and use condoms if their partner can procreate, during&#xD;
             all the treatment period, during dose interruptions and for at least 4 weeks after&#xD;
             study drug discontinuation.&#xD;
&#xD;
         12. Signed inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to any drug contained in the chemotherapy regimen or to any of their&#xD;
             excipients&#xD;
&#xD;
          2. T-cell lymphoma&#xD;
&#xD;
          3. Diagnosis of any second malignancy within the last 5 years&#xD;
&#xD;
          4. Prior history of organ transplantation or other cause of severe immunodeficiency&#xD;
&#xD;
          5. History of heart disease and/or impaired cardiac function (ECG QTc&gt;450msec, congenital&#xD;
             long QT syndrome, history of ventricular tachyarrhythmia, ventricular fibrillation,&#xD;
             congestive heart failure NYHA III/IV, uncontrolled hypertension).&#xD;
&#xD;
          6. Known HIV or HTLV-1 infection, positive serology to HB surface antigen [HBsAg] or&#xD;
             total HB core antibody [anti-HB-c]) and Hepatitis C (Hepatitis C virus [HCV] antibody)&#xD;
             not older than 4 weeks&#xD;
&#xD;
          7. Inclusion in another experimental anti-cancer drug therapy*&#xD;
&#xD;
          8. Impossibility to follow the calendar of exams because of geographic, social or&#xD;
             psychological reasons&#xD;
&#xD;
          9. Patient under measure of legal protection&#xD;
&#xD;
         10. No social security *For ethical reasons, the exclusion period within which the patient&#xD;
             cannot be included in another trial will not be defined but discussed on a case to&#xD;
             case basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole SOUSSAIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie - Hopital Rene Huguenin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau - Centre Henry Kaplan</name>
      <address>
        <city>Tours</city>
        <state>Centre</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Ile De France</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Michallon</name>
      <address>
        <city>Grenoble</city>
        <state>Isère</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <state>Lorraine</state>
        <zip>54036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhône-Alpes</state>
        <zip>39373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <state>Seine Maritime</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens -Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/30698644/</url>
    <description>Related Info</description>
  </link>
  <results_reference>
    <citation>Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.</citation>
    <PMID>30698644</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

